Showing 17,381 - 17,400 results of 44,759 for search '(( 5 ((ng decrease) OR (mean decrease)) ) OR ( 50 ((a decrease) OR (teer decrease)) ))', query time: 1.18s Refine Results
  1. 17381
  2. 17382

    Simulating non-small cell lung cancer with a multiscale agent-based model-2 by Zhihui Wang (88248)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "Simulating non-small cell lung cancer with a multiscale agent-based model"</p><p>http://www.tbiomed.com/content/4/1/50</p><p>Theoretical Biology & Medical Modelling 2007;4():50-50.…”
  3. 17383

    Supplementary Material for: Surfactant Treatment of Late Preterm Infants during Emergency Transport: A Retrospective, Observational Study by Cavallin F. (11448277)

    Published 2021
    “…<b><i>Results:</i></b> Surfactant was administered to 155/303 neonates (51.1%) at 3 different time points: at a referring hospital (50 neonates), when the transport team arrived (25 neonates), or at a referral hospital (80 neonates). …”
  4. 17384

    NF-κB p65 and phosphorylation of IκBα <i>in vitro</i>. by Naoki Takada (2728912)

    Published 2021
    “…<p>(A) The enzyme-linked immunosorbent assay (ELISA) results showed that p65 concentration in the radiation group was higher than that in the control group (NOZ: 2,398.4 ± 62.8 ng/mg protein vs. 923.5 ± 42.3 ng/mg protein, p < 0.01; OCUG-1: 2,609.3 ± 409.3 ng/mg protein vs. 1,899.5 ± 99.5 ng/mg protein, p < 0.05). p65 concentration in the combination group was lower than that in the radiation group (NOZ: 1,256.1 ± 13.0 ng/mg protein vs. 2,398.4 ± 62.8 ng/mg protein, p < 0.01; OCUG-1: 1,250.9 ± 117.8 ng/mg protein vs. 2,609.3 ± 409.3 ng/mg protein, p < 0.01). …”
  5. 17385

    Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients by Sana Mohsin (19773969)

    Published 2024
    “…</p> <p><b>Results:</b> 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33–0.82); <i>p</i> = 0.005; I<sup>2</sup>= 32%], HF hospitalization [RR = 0.20 (0.04–1.02); <i>p</i> = 0.05; I<sup>2</sup>= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20–1.16); <i>p</i> = 0.11, I<sup>2</sup>= 0%].…”
  6. 17386

    Mitotic regeneration of IPhCs. by Tomokatsu Udagawa (11675636)

    Published 2021
    “…(O) Significantly more EdU<sup>+</sup> Sox2<sup>+</sup> cells were detected throughout the P7 IPhC regions of DT-treated <i>Lgr5</i><sup><i>DTR/+</i></sup> cochlea relative to controls, decreasing in an apical–basal gradient. …”
  7. 17387

    The Efficacy of Hyperbaric Oxygen Therapy on Middle Cerebral Artery Occlusion in Animal Studies: A Meta-Analysis by Yang Xu (178421)

    Published 2016
    “…Subgroup analysis showed that a maximal neuro-protective effect was reached when HBO was administered immediately after MCAO with an absolute atmospheric pressure (ATA) of 2.0 (50% decrease; 95% CI, 43% -57% decrease; <i>p</i> < 0.0001) and more than 6 hours HBO treatment (53% decrease; 95% CI, 41% -64% decrease; <i>p</i> = 0.0005).…”
  8. 17388

    Data_Sheet_1_Mindfulness Training for Primary Care for Portuguese-Speaking Immigrants: A Pilot Study.docx by Marcelo Trombka (11411288)

    Published 2021
    “…All survey finishers would recommend the program to a friend, found the program helpful, and rated the overall program as “very good” or “excellent,” and 93% would participate again, with satisfaction mean scores between 4.6 and 5 (Likert scale 0–5). …”
  9. 17389
  10. 17390

    Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial by Beatrice A. Golomb (140574)

    Published 2015
    “…</p><p>Trial Registration</p><p>Clinicaltrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT00330980" target="_blank">NCT00330980</a></p></div>…”
  11. 17391

    Table_1_Clinical Characteristics and Immune Responses of 137 Deceased Patients With COVID-19: A Retrospective Study.docx by Ning Cui (502137)

    Published 2020
    “…Our analysis revealed that age ≥ 65 years, male sex, malignancy, chronic obstructive pulmonary disease, dyspnea, dizziness, respiratory rate > 20 bpm, heart rate > 100 bpm, systolic blood pressure < 90 mmHg, neutrophils > 6.3×109/L, lymphopenia, thrombocytopenia, D-dimer ≥ 0.5 mg/L, lactate dehydrogenase > 250 U/L, aspartate aminotransferase > 40 U/L, total bilirubin > 26 μmol/L, albumin < 35 g/L, blood urea nitrogen > 9.5 mmol/L, estimated glomerular filtration rate < 90 ml/min/1.73, elevated cardiac troponin I, N-terminal pro-brain natriuretic peptide ≥ 900 pg/ml, C-reactive protein ≥ 25 mg/L, procalcitonin ≥ 0.05 ng/ml and ferritin > 400 μg/L were associated with death in patients with COVID-19. …”
  12. 17392
  13. 17393

    Developmental and Neurobehavioral Toxicity of Hexaphenoxycyclotriphosphazene: Implications for Its Safety as a Flame-Retardant Alternative to Triphenyl Phosphate by Ruobing Bai (4860043)

    Published 2025
    “…HPCTP caused dose-dependent depression-like behaviors (hypoactivity, light-zone avoidance) through suppression of serotonin 1A (5-HT<sub>1</sub>A) signaling, supported by decreased <i>htr1aa</i> expression and serotonin levels and partially rescued by the 5-HT<sub>1</sub>A receptor agonist 8-OH-DPAT. …”
  14. 17394

    Neutralization of point mutants of B.1.351 and D614G spike-pseudotyped lentiviral particles by convalescent plasmas from B.1.351 and early 2020-infected individuals. by Allison J. Greaney (11046384)

    Published 2022
    “…<b>(B)</b> The fold-decrease in neutralization for samples shown in <b><a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1010248#ppat.1010248.g005" target="_blank">Fig 5</a></b>, with the addition of previously measured neutralization by samples from 6 early 2020 convalescent individuals collected approximately 100 days post-symptom onset [<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1010248#ppat.1010248.ref038" target="_blank">38</a>]. …”
  15. 17395

    A reduction in brain mass and cortical volume seen in the adult <i>Cln6<sup>nclf</sup></i> mouse. by Jeremy P. Morgan (479017)

    Published 2013
    “…<p>Brain mass was assessed in the <i>Cln6<sup>nclf</sup></i>, as a decrease in brain mass is often seen in vLINCL patients. …”
  16. 17396
  17. 17397
  18. 17398

    Frequency trajectories of iSNVs that fluctuated (Top) and their positions on the genome (Bottom) (patients A-I). by Lele Zhao (532080)

    Published 2025
    “…<p>The inclusion criterion was iSNVs that changed from below 50% at Baseline (i.e., 0 days post baseline), to above 50% at PT12 (12 weeks post treatment), and decreased to below 50% at PT24 (24 weeks post treatment). …”
  19. 17399

    New advances in <i>DPYD</i> genotype and risk of severe toxicity under capecitabine - Fig 3 by Marie-Christine Etienne-Grimaldi (413881)

    Published 2017
    “…<p>Distribution of pre-treatment plasma UH2/U ratio (A) and Uracil concentrations (B) for the 205 patients with validated phenotypic data, according to <i>DPYD</i> variants of interest: variant *2A (3 heterozygous patients), D949V (3 heterozygous patients), R592W (1 heterozygous patient), D342G (1 heterozygous patient), HapB3 (4 heterozygous patients), 166VV (3 homozygous patients) <i>vs</i> any other variations (185 patients) <i>vs</i> no variation (5 patients). …”
  20. 17400

    Adverse event list. by Stefan Halbherr (21353882)

    Published 2025
    “…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”